News and Announcements
Government grant to support Melbourne Dental School Oral Cancer Trial
- Published July 20, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OptiScan Imaging Limited (ASX: OIL (‘the Company’ or‘OptiScan’), has been awarded a grant of almost $1 million by the Australian Government, which will help fund a trial to improve screening, diagnosis and treatment of oral cancer.
The BioMedTech Horizons Program is an initiative of the Medical Research Future Fund, operated by MTPConnect. It is designed to foster innovative collaborative health technology development, and stimulate collaboration across disciplines and between the research, industry, and technology sectors to maximise entrepreneurship and idea potential.
The Program’s latest round of funding, was open to medical device projects targeting innovative solutions to address unmet clinical needs in three key focus areas, including general medical devices in oncology.
To read the full ASX announcement, click here.
About Optiscan
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early-stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
